COVID-19 vaccine: Early data on efficacy expected by mid-Sept; all you need to know

COVID-19 vaccines’ early data that could prove its efficacy and an eventual go-ahe for manufacture is expected to come as early as this month, according to a report by a US-based analytics company that tracks drug trials. Airfinity Ltd revealed in a report that results for human clinical trials of experimental vaccine by AstraZeneca Plc will be declared mid-September as US federal government asks states to prepare for a coronavirus vaccine and make provisions to distribute it by vember 1.

Meanwhile, US’s Moderna Inc. and potential vaccine manufactured by US-German partnership of Pfizer Inc. and BioNTech SE will shortly provide its results on October 22. China's Sivac Biotech Ltd. vaccine, fourth candidate on record has also indicated to schedule results shortly after FDA meeting. 

Airfinity Chief Executive Officer Rasmus Bech Hansen in an interview with a Danish daily Finans said that results would give a great idea about where world stood in terms of ir search for COVID-19 vaccine. He also informed that companies were progressing faster than anticipated, and final results should be sufficient to introduce vaccine to world. Airfinity’s data has been based on publicly available data on trial enrollment for companies. While most vaccines currently under different sts of human trials have shown progress, re has been eugh evidence of experimental vaccines fighting COVID-19 by creating a response in immune system. 

Re: China Offers Experimental COVID-19 Vaccine To Aviation Sector Employees: Report

Re: India's Daily COVID-19 Testing Numbers One Of Highest In World: Health Ministry

Letter related to distribution of vaccines

Director of US Centers for Disease Control and Prevention h stated in a letter dated August 27, accessed by AP, saying that states “in near future” shall expect a permit application from McKesson Corp which has a contract with CDC for distribution of COVID-19 vaccines.

“CDC urgently requests your assistance in expediting applications for se distribution facilities and, if necessary, asks that you consider waiving requirements that would prevent se facilities from becoming fully operational by vember 1, 2020,” Redfield wrote. ditionally, three documents that list timelines for when vaccines will be available were also sent to health departments, as per AP report. “ COVID-19 vaccine landscape is evolving and uncertain, and se scenarios may evolve as more information is available,” document mentioned. 

Meanwhile, director of Oxford Vaccine Group Andrew Pollard said in a statement that University of Oxford and AstraZeneca’s experimental COVID-19 vaccine would be sent to regulators this year if scientists and experts are able to cumulate positive data from results. Pollard said that it may be possible that if cases accrue rapidly in clinical trials, company could have that data before regulators soon. 

Re: Likely Disruption Of Production In Short Term, Due To COVID-19: HAL CMD

Re: Dwayne Johnson Opens Up On COVID-19 Struggle, Fans Have Mixed Reactions On Social Media